CRISPR & Cas Genes Market Size Attain USD 17.49 Billion By 2034

Table of Contents

The global CRISPR & Cas genes market size was valued at USD 3.67 billion in 2024 and is anticipated to attain around USD 17.49 billion by 2034, growing at a CAGR of 16.90%.

Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/1108

Key Points

With a 39% share in 2024, North America remained the dominant region in the global market.
Asia Pacific is forecasted to grow at the fastest CAGR during the projected period.
The biomedical segment recorded the highest market share by application in 2024.
The product segment was the key contributor to revenue within the product & service division.
The biotechnology and pharmaceutical industry represented the largest end-user segment in 2024.

Drivers

The CRISPR & Cas genes market is being propelled by the increasing need for innovative gene-editing solutions in both healthcare and agriculture. The ability of CRISPR technology to target and modify specific genetic sequences with high precision has revolutionized the field of genetic engineering.

The growing interest in developing CRISPR-based treatments for inherited diseases, cancer, and infectious diseases is further boosting market demand. Additionally, advancements in delivery mechanisms, such as nanoparticle-based CRISPR systems, are enhancing the efficiency of gene-editing applications.

Opportunities

The growing acceptance of CRISPR in synthetic biology and biopharmaceutical research is expanding the market’s potential. The ability to engineer microorganisms for biofuel production, environmental conservation, and industrial applications presents new commercial opportunities.

The ongoing research into CRISPR-based antiviral therapies, particularly for HIV and COVID-19, is also expected to drive future growth. Furthermore, the increasing affordability of CRISPR technology is making it more accessible to smaller biotech firms and academic research institutions, fostering innovation in the field.

Challenges

While CRISPR technology holds great promise, concerns regarding its safety and ethical implications continue to pose significant challenges. The possibility of creating permanent genetic alterations in humans raises moral and regulatory questions.

Furthermore, technical limitations, such as delivery efficiency and immune responses to CRISPR components, require further research and development. The potential for intellectual property disputes over CRISPR patents among leading biotech firms also adds complexity to market competition.

Regional Analysis

North America continues to be the leading market for CRISPR & Cas genes, supported by a strong ecosystem of research institutions, government funding, and private investments. Europe remains a key market due to increasing support for precision medicine and advancements in genetic research.

The Asia-Pacific region is rapidly emerging as a major market, driven by expanding biotechnology industries, government initiatives, and rising adoption of CRISPR in agriculture and healthcare. Latin America and the Middle East & Africa are still in the early stages of CRISPR adoption but are gradually gaining momentum with improvements in healthcare infrastructure and research funding.

CRISPR & Cas Genes Market Companies

Caribou Biosciences, Inc.
F. Hoffmann-La Roche Ltd.
Cellectis
AstraZeneca
Editas Medicine, Inc.
Addgene
Egenesis
Horizon Discovery Group Plc
Intellia Therapeutics, Inc.
Genscrip
Danaher Corporation
Lonza
Merck KGaA
Synthego
Mammoth Biosciences
Inscripta, Inc.
Cibus
New England BioLabs
Takara Bio, Inc.

Segments Covered in the Report

By Product & Service

By Service
- Microbial Gene Editing
- Cell Line Engineering
- gRNA Design
- DNA Synthesis
By Product
- Design Tool
- Kits & Enzymes
- Libraries
- Antibodies
- Others

By Application

Agricultural
Biomedical
- Functional Genomics
- Genome Engineering
- Disease Model Studies
- Epigenetics
- Others

End-use Outlook

- Contract Research Organizations (CROs),
- Academics & Government Research Institutes
- Biotechnology & Pharmaceutical Companies

By Regional Outlook

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia Pacific
- China
- India
- Japan
- South Korea
Middle East & Africa
Latin America

Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/

Author
Recent Posts

akshay dhamal